+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Gastroesophageal Reflux Disease Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454843
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers seeking strategic insight into the gastroesophageal reflux disease therapeutics market will find this report crucial for steering business priorities. It delivers integrated intelligence on evolving clinical practices, commercial dynamics, and regulatory requirements shaping tomorrow’s patient care and competition.

Market Snapshot: Gastroesophageal Reflux Disease Therapeutics Market

The gastroesophageal reflux disease therapeutics market expanded from USD 5.46 billion in 2025 to USD 5.74 billion in 2026 and is projected to reach USD 7.88 billion by 2032, at a CAGR of 5.36%.

Growth in this segment is driven by advancements in acid suppression therapies, increased emphasis on value-based pricing, shifts toward outpatient management, and growing demands for improved supply chain agility. Evolving patient expectations, combined with accelerated digital innovation, are influencing not just product pipelines but also distribution strategies and care delivery. Senior leaders must recognize the interplay of these drivers for sustainable market presence.

Scope & Segmentation

This report provides an in-depth analysis of the gastroesophageal reflux disease therapeutics landscape across a full spectrum of market segments, regions, and care settings. By examining the market through clinical, commercial, and operational lenses, the study allows for actionable insight at every level of the value chain:

  • Treatment Classes: Antacids, H2 receptor antagonists (covering both branded and generic products), proton pump inhibitors, and prokinetics are fully profiled to illustrate differences in mechanism of action, safety, and patient outcomes.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies are assessed, reflecting the rise of direct-to-patient models and evolving procurement processes.
  • Administration Routes: Intravenous and oral delivery methods are analyzed to capture their relevance in both acute and chronic care environments as organizations tailor to patient acuity.
  • Dosage Forms: Capsule, liquid, suspension, and tablet formats are detailed to support therapeutic decision-making for diverse demographics.
  • Patient Care Settings: Home care, hospitals, and specialty clinics are studied, highlighting differing care pathways, compliance factors, and buyer dynamics.
  • Geographic Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific are compared, underscoring regional adaptations in therapy access, payer models, and regulatory environments.

Beyond classic segmentation, this report evaluates the impact of digital health solutions and integrated adherence platforms used in both product innovation and patient engagement strategies on a global scale. These tools play a growing role in tailoring treatment and meeting population-specific needs across multiple markets.

Key Takeaways for Senior Decision-Makers

  • Therapeutic approaches are diversifying, with manufacturers increasingly prioritizing patient-centric outcomes and sustainable symptom management.
  • Regulatory agencies are adapting to new models of evidence generation, leading to quicker market entry for differentiated offerings supported by real world data.
  • Expansion of specialty and online pharmacy channels is reshaping access pathways, emphasizing the importance of omnichannel delivery and stronger supply partnerships.
  • Operational resilience has become a core objective, prompting leaders to reinforce sourcing diversification and manufacturing alliances for stable continuity.
  • Emerging versus established regions require nuanced strategies that balance the realities of payer negotiations, access logistics, and regional purchasing power.
  • Targeted M&A, alliances, and flexible partnership models are central for companies seeking to grow portfolios while mitigating market risk and optimizing commercialization.

Tariff Impact: Implications of United States Policy Adjustments

Modifications in US tariff policy have reshaped therapeutic supply chains and price structures across the gastroesophageal reflux disease therapeutics market. Manufacturers with global supply networks are facing greater input cost variability, resulting in supplier contract renegotiations and a deliberate shift toward nearshoring strategies. These operational adjustments aim to balance increased fixed expenses with better supply dependability. For payors, the evolving tariff landscape adds complexity to pricing structure negotiations, further intensifying the requirement for clear evidence of economic value and detailed risk-sharing in supplier contracts. Organizations leveraging diversified operations and adaptable partnerships are positioned to minimize the effects of policy disruption.

Methodology & Data Sources

This research employs a triangulated approach, integrating firsthand interviews with healthcare professionals, pharmacy directors, and sourcing specialists, alongside secondary analyses from clinical trial registries, regulatory releases, and peer-reviewed scientific studies. Comprehensive segmentation mapping, scenario modeling, and stakeholder feedback address current trends and potential future scenarios, ensuring robust and relevant conclusions.

Why This Report Matters

  • Enables leaders to align R&D, regulatory, and commercial priorities for more precise strategic decisions in a competitive treatment market.
  • Supplies actionable guidance on operational risk mitigation and long-term resilience strategies in response to ongoing supply and tariff evolutions.
  • Equips organizations with the intelligence required for effective regional adaptation and focused go-to-market planning in the field of GERD therapeutics.

Conclusion

The gastroesophageal reflux disease therapeutics market embodies rapid innovation, evolving regulatory and patient expectations, and increasingly complex distribution models. Companies synthesizing clinical data, operational adaptability, and targeted regional strategies will be positioned for competitive strength and improved patient access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type
8.1. Pharmacologic Therapies
8.1.1. Proton Pump Inhibitors (PPIs)
8.1.2. H2 Receptor Antagonists
8.1.3. Antacid
8.1.4. Mucosal Coating Agent
8.1.4.1. Sucralfate & Coating Agents
8.1.4.2. Alginates/Raft Formers
8.2. Surgical Interventions
8.3. Device-Based Therapies
9. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form
9.1. Capsule
9.2. Liquid
9.3. Suspension
9.4. Tablet
10. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration
10.1. Oral
10.2. Injectable
11. Gastroesophageal Reflux Disease Therapeutics Market, by Medicine Type
11.1. Over-The-Counter
11.2. Prescription
12. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Status
12.1. Branded
12.2. Generic
13. Gastroesophageal Reflux Disease Therapeutics Market, by Disease Severity
13.1. Mild
13.2. Moderate
13.3. Severe
14. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel
14.1. Hospital Pharmacies
14.2. Online Pharmacies
14.3. Retail Pharmacies
15. Gastroesophageal Reflux Disease Therapeutics Market, by End User
15.1. Home Care Settings
15.2. Hospitals
15.3. Specialty Clinics
16. Gastroesophageal Reflux Disease Therapeutics Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Gastroesophageal Reflux Disease Therapeutics Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Gastroesophageal Reflux Disease Therapeutics Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Gastroesophageal Reflux Disease Therapeutics Market
20. China Gastroesophageal Reflux Disease Therapeutics Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. AstraZeneca plc
21.6. Aurobindo Pharma Limited
21.7. Bayer AG
21.8. Cadila Pharmaceuticals Ltd.
21.9. Camber Pharmaceuticals, Inc.
21.10. Daewoong Pharmaceutical Co., Ltd.
21.11. Dr. Reddy’s Laboratories Limited
21.12. Eisai Co., Ltd.
21.13. Elite Wealth Ltd.
21.14. Haleon plc
21.15. HK inno.N Co., Ltd.
21.16. Ironwood Pharmaceuticals, Inc.
21.17. Johnson & Johnson Services, Inc.
21.18. Lupin Limited
21.19. Onconic Therapeutics Inc.
21.20. Pfizer Inc.
21.21. Phathom Pharmaceuticals, Inc.
21.22. RaQualia Pharma Inc.
21.23. Reckitt Benckiser Group plc
21.24. Sandoz Group AG
21.25. Sanofi S.A.
21.26. Sebela Pharmaceuticals Inc.
21.27. Sun Pharmaceutical Industries Limited
21.28. Takeda Pharmaceutical Company Limited
21.29. Teva Pharmaceutical Industries Ltd.
21.30. The Procter & Gamble Company
21.31. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUCRALFATE & COATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ALGINATES/RAFT FORMERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DEVICE-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 144. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 145. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 148. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 150. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 165. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 166. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 167. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 168. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 172. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 189. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 190. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 191. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 193. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 195. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 198. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 200. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 201. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 202. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 204. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 205. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 206. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 221. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 222. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 223. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 224. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 226. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 227. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 228. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 232. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 233. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 234. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 235. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 237. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 238. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 239. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 242. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 244. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 245. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 246. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 248. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 249. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 250. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. UN

Companies Mentioned

The key companies profiled in this Gastroesophageal Reflux Disease Therapeutics market report include:
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Camber Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Eisai Co., Ltd.
  • Elite Wealth Ltd.
  • Haleon plc
  • HK inno.N Co., Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Onconic Therapeutics Inc.
  • Pfizer Inc.
  • Phathom Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Reckitt Benckiser Group plc
  • Sandoz Group AG
  • Sanofi S.A.
  • Sebela Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.88 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Gastroesophageal Reflux Disease Therapeutics Market Report 2025 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 132 Pages
  • Global
From
Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report - Product Image

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Gastroesophageal Reflux Disease (Gerd) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Gastroesophageal Reflux Disease (Gerd) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.